First Participant Dosed in Phase III Obesity/Overweight Study of UBT251 Injection by United Lab

Stock News09-04

United Lab (03933) has announced that its wholly-owned subsidiary, United Biomedical Technology (Zhuhai Hengqin) Co., Ltd., has completed the first participant dosing for its independently developed Class 1 innovative drug, UBT251 injection, in a Phase III clinical study for overweight and obesity in China.

The study employs a randomized, double-blind, parallel, placebo-controlled design, planning to enroll 600 participants who are obese (BMI ≥ 28.0 kg/m²) or overweight with at least one weight-related comorbidity (24.0 kg/m² ≤ BMI < 28.0 kg/m²). The trial aims to evaluate the efficacy and safety of UBT251 injection in this patient population.

The primary endpoints of the study include the percentage change in body weight from baseline at 52 weeks of treatment, as well as the proportion of participants achieving a weight reduction of 5% or more from baseline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1101782990?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-04 18:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101782990","market":"hk","top_or_hot":-1,"title":"First Participant Dosed in Phase III Obesity/Overweight Study of UBT251 Injection by United Lab","media":"Stock News","content":"<p><b>United Lab (03933)</b> has announced that its wholly-owned subsidiary, United Biomedical Technology (Zhuhai Hengqin) Co., Ltd., has completed the first participant dosing for its independently developed Class 1 innovative drug, UBT251 injection, in a Phase III clinical study for overweight and obesity in China.<br><br>The study employs a randomized, double-blind, parallel, placebo-controlled design, planning to enroll 600 participants who are obese (BMI ≥ 28.0 kg/m²) or overweight with at least one weight-related comorbidity (24.0 kg/m² ≤ BMI < 28.0 kg/m²). The trial aims to evaluate the efficacy and safety of UBT251 injection in this patient population.<br><br>The primary endpoints of the study include the percentage change in body weight from baseline at 52 weeks of treatment, as well as the proportion of participants achieving a weight reduction of 5% or more from baseline.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>First Participant Dosed in Phase III Obesity/Overweight Study of UBT251 Injection by United Lab</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFirst Participant Dosed in Phase III Obesity/Overweight Study of UBT251 Injection by United Lab\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-04 18:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>United Lab (03933)</b> has announced that its wholly-owned subsidiary, United Biomedical Technology (Zhuhai Hengqin) Co., Ltd., has completed the first participant dosing for its independently developed Class 1 innovative drug, UBT251 injection, in a Phase III clinical study for overweight and obesity in China.<br><br>The study employs a randomized, double-blind, parallel, placebo-controlled design, planning to enroll 600 participants who are obese (BMI ≥ 28.0 kg/m²) or overweight with at least one weight-related comorbidity (24.0 kg/m² ≤ BMI < 28.0 kg/m²). The trial aims to evaluate the efficacy and safety of UBT251 injection in this patient population.<br><br>The primary endpoints of the study include the percentage change in body weight from baseline at 52 weeks of treatment, as well as the proportion of participants achieving a weight reduction of 5% or more from baseline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03933","symbol_name":"联邦制药","start_time":0,"source_url":"","article_id":"1101782990","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101782990","pubTimestamp":1788519494,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"United Lab (03933) has announced that its wholly-owned subsidiary, United Biomedical Technology (Zhuhai Hengqin) Co., Ltd., has completed the first participant dosing for its independently developed...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03933":"联邦制药","IE00B3M56506.USD":"NEUBERGER BERMAN EMERGING MARKETS EQUITY \"A\" (USD) ACC","BK1191":"制药"},"translate_title":"United Lab UBT251注射液III期肥胖/跑赢大盘病研究中的首位受试者给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03933":1},"content_text":"United Lab (03933) has announced that its wholly-owned subsidiary, United Biomedical Technology (Zhuhai Hengqin) Co., Ltd., has completed the first participant dosing for its independently developed Class 1 innovative drug, UBT251 injection, in a Phase III clinical study for overweight and obesity in China.The study employs a randomized, double-blind, parallel, placebo-controlled design, planning to enroll 600 participants who are obese (BMI ≥ 28.0 kg/m²) or overweight with at least one weight-related comorbidity (24.0 kg/m² ≤ BMI < 28.0 kg/m²). The trial aims to evaluate the efficacy and safety of UBT251 injection in this patient population.The primary endpoints of the study include the percentage change in body weight from baseline at 52 weeks of treatment, as well as the proportion of participants achieving a weight reduction of 5% or more from baseline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1101782990","isCrawlerRequest":true}